Replies to post #17888 on CytoSorbents Corporation (CTSO)

[techxen]

The suppressed share price this year in my opinion is due to the slow pace of recruitment and the lack of significant progress on the clinical front, combined with the hit piece on Seeking Alpha earlier this year, the price has never recovered.

Operationally the company is still making strides towards operating cash flow breakeven which together with the recent government grants, at least minimizes the risk of further dilution while the trials progress.

With approval dates now out at the earliest 2021 (assuming Hemodefend starts early next year) and potentially 2022-2023 with REFRESH, barring any partnership announcement, the share price will likely remain in a low trading range. I think some of the institutions probably realize that approval is a ways a way and there are better places to park their money.

[J G R]

That's because they don't promote anything except when Dr. Chan goes to another conference. It's like they don't care that the stock that the stock has lost 2/3 of it's value in the past year. We would learn nothing of whats going on if it were not for the smart guys like techexn and others like him on this board.